Clinical Trials Logo

Recurrent Childhood Brain Neoplasm clinical trials

View clinical trials related to Recurrent Childhood Brain Neoplasm.

Filter by:
  • None
  • Page 1

NCT ID: NCT02444546 Suspended - Glioma Clinical Trials

Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors

Start date: June 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of wild-type reovirus (viral therapy) when given with sargramostim in treating younger patients with high grade brain tumors that have come back or that have not responded to standard therapy. A virus, called wild-type reovirus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Sargramostim may increase the production of blood cells and may promote the tumor cell killing effects of wild-type reovirus. Giving wild-type reovirus together with sargramostim may kill more tumor cells.

NCT ID: NCT00978562 Active, not recruiting - Clinical trials for Recurrent Childhood Brain Neoplasm

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

Start date: August 2009
Phase: N/A
Study type: Interventional

This clinical trial studies dynamic susceptibility-weighted contrast enhanced magnetic resonance imaging (DSC-MRI) after administration of ferumoxytol and dynamic contrast-enhanced MRI (DCE-MRI) after administration of a gadolinium-based contrast agent (GBCA) in viewing the vessels of the brain in younger patients with brain tumors. Ferumoxytol is an experimental form of very small iron particles that are taken by the blood stream to cells adjacent and inside the tumor. These iron particles may make it easier to see the areas of the brain that are affected by tumor. Ferumoxytol may work better than standard GBCA in viewing the vessels of the brain and brain tumor on MRI. Using ferumoxytol and GBCA in the same MRI session may provide more information about tumor blood supply and the extent of the tumor.

NCT ID: NCT00326664 Completed - Clinical trials for Recurrent Childhood Medulloblastoma

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Start date: March 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.